There are currently 2877 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®
NCT05900050
Recruiting
A Phase 2, multi-center, randomized, controlled, open-label study to evaluate the effects of the intraperitoneal, liposomal formulation VS-01 in patients with an acute episode of hepatic and/or extrahepatic organ dysfunctions and failures in the presence of liver cirrhosis (Acute-on-Chronic Liver Failure, ACLF) and accumulation of fluid in the abdominal cavity (ascites)
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
08/14/2025
Locations: Baylor Clinic, Houston, Texas
Conditions: Acute-On-Chronic Liver Failure, Ascites
Register for Updates
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
NCT06096779
Recruiting
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-Pugh B7 or B8 cirrhosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Kelsey Research Foundation, Houston, Texas +2 locations
Conditions: Hepatocellular Carcinoma
Register for Updates
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034
Recruiting
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/14/2025
Locations: Houston Methodist Hospital, Houston, Texas +3 locations
Conditions: Ischemic Stroke; Ischemic Attack, Transient
Register for Updates
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
NCT06008093
Recruiting
The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRAS.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
08/14/2025
Locations: Research Site, Houston, Texas +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
NCT02734537
Recruiting
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet kno... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: M D Anderson Cancer Center, Houston, Texas +1 locations
Conditions: Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant, Lip and Oral Cavity Squamous Cell Carcinoma, p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oral Cavity Verrucous Carcinoma, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Register for Updates
A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
NCT05578092
Recruiting
This is a Phase 1/2, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy harboring mutations in the KRAS-MAPK pathways.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor, Advanced Solid Tumor, Non Small Cell Lung Cancer, Colo-rectal Cancer
Register for Updates
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
NCT06870487
Recruiting
The purpose of this study is to learn about the effects of a new study medicine called PF-08046032, when taken alone and when taken with another medicine called sasanlimab, for the treatment of advanced cancers. The effects are studied in adult participants with certain types of lymphomas or solid tumors that are advanced or metastatic (spread to other parts of the body). The study has three parts: * Part A will test PF-08046032 alone at increasing dose levels in participants with certain lymp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma, Classical Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer
Register for Updates
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803
Recruiting
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/14/2025
Locations: Research Site, Houston, Texas
Conditions: Systemic Sclerosis, Scleroderma
Register for Updates
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
NCT06898957
Recruiting
The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/14/2025
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Small Cell Lung Cancer
Register for Updates
Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)
NCT07047716
Recruiting
The goal of this clinical study is to learn more about the study drug lenacapavir (LEN), safety, tolerability, and pharmacokinetics (how LEN is absorbed, modified, distributed, and removed from the body of the participants) of once-yearly intramuscular for HIV pre-exposure prophylaxis (PrEP) in people with an indication for PrEP. The primary objective of this study is to evaluate the pharmacokinetics (PK) and the safety and tolerability of intramuscular (IM) every 12 months (Q12M) LEN for PrEP... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
08/14/2025
Locations: The Crofoot Research Center, Houston, Texas
Conditions: HIV Pre-exposure Prophylaxis
Register for Updates
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of K-645 in the Treatment of Multiple Migraine Attacks
NCT07116499
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, 3-period crossover study to evaluate the safety, tolerability, and efficacy of two dose levels of K-645 in the treatment of patients with acute migraine.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/14/2025
Locations: DM Clinical Research - Bellaire, Houston, Texas
Conditions: Acute Migraine
Register for Updates
A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults
NCT07019883
Recruiting
This is a phase 1, multicenter, randomized, double-blind trial of two influenza A/H5 mRNA-based vaccines on healthy adult participants, 18-49 years of age. Stage 1 will serve as the open-label, dose finding stage. The first 10 participants will receive 12.5 mcg of H5 AC-Anhui RNA vaccine (Group 1), and the second 10 participants will receive 25 mcg of H5 AC-Anhui RNA vaccine (Group 2). After Protocol Safety Review Team (PSRT) review of reactogenicity and safety data through Day 8 for both Groups... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
08/14/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Avian Influenza
Register for Updates